26268-23-5

Usage

Uses

Used in Pharmaceutical Research and Development:
2-Benzoimidazol-1-yl-phenylamine is employed as a key component in the development of new drugs, leveraging its unique chemical structure and properties to target various medical conditions.
Used in Cancer Treatment:
In the field of oncology, 2-benzoimidazol-1-yl-phenylamine is used as a potential therapeutic agent for treating various types of cancer. Its specific mechanism of action and interaction with cellular targets are under investigation to determine its efficacy and safety in clinical settings.
Used in Neurodegenerative Disease Treatment:
2-BENZOIMIDAZOL-1-YL-PHENYLAMINE is also being studied for its potential to treat neurodegenerative diseases, where it may offer neuroprotective effects or modulate disease pathways, thereby slowing disease progression or alleviating symptoms.
Used in Antimicrobial Applications:
2-Benzoimidazol-1-yl-phenylamine exhibits antimicrobial properties, making it a candidate for the development of new antibiotics to combat drug-resistant bacterial strains.
Used in Antifungal Applications:
Similarly, its antifungal properties suggest potential use in developing new antifungal agents to treat fungal infections, particularly those that have become resistant to existing treatments.
Used in Drug Delivery Systems:
To enhance the bioavailability, delivery, and therapeutic outcomes of 2-benzoimidazol-1-yl-phenylamine, researchers are exploring various drug delivery systems, including organic and metallic nanoparticles, to improve its clinical effectiveness and safety profile.

InChI:InChI=1/C13H11N3/c14-10-5-1-3-7-12(10)16-9-15-11-6-2-4-8-13(11)16/h1-9H,14H2

Upstream product

• 25688-28-2 1‐(2‐nitrophenyl)‐1H‐benzo[d]imidazole 
• 51-17-2 benzoimidazole 
• 615-36-1 2-bromoaniline 
• 1493-27-2 ortho-nitrofluorobenzene 
• 609-73-4 o-nitroiodobenzene 

Downstream Products

• 1352820-89-3 5-phenyl-5H-benzo[d]benzo[4,5]imidazo[1,2-a]imidazole 
• 1352820-65-5 N-(2-(1H-benzo[d]imidazol-1-yl)phenyl)-3,5-dimethylaniline 
• 1352820-62-2 2-(1H-benzo[d]imidazol-1-yl)-N-p-tolylaniline 
• 1352820-63-3 2-(1H-benzo[d]imidazol-1-yl)-N-m-tolylaniline 
• 1352820-66-6 2-(1H-benzo[d]imidazol-1-yl)-N-(4-chlorophenyl)aniline 
• 1352820-93-9 5-(4-chlorophenyl)benzimidazo[1,2-a]benzimidazole 
• 1352820-92-8 5-(3,5-dimethyphenyl)benzimidazo[1,2-a]benzimidazole 
• 1352820-91-7 5-(3-methyphenyl)benzimidazo[1,2-a]benzimidazole 
• 1352820-90-6 5-(4-methyphenyl)benzimidazo[1,2-a]benzimidazole 
• 1352820-61-1 2-(1H-benzo[d]imidazol-1-yl)-N-phenylaniline 

Relevant academic research and scientific papers

Facile synthesis of C6-substituted benz[4,5]imidazo[1,2-a]quinoxaline derivatives and their anticancer evaluation

Cancer remains a leading cause of death worldwide, resulting in continuous efforts to discover and develop highly efficacious anticancer drugs. High-throughput screening of heterocyclic compound libraries is one of the promising approaches that provided several new lead molecules with a novel mechanism of action. On the basis of the promising anticancer potential of imidazoquinoxaline as well as the structurally similar imidazoquinoline-derived scaffold, we prepared a set of C6-substituted benzimidazo[1,2-a]quinoxaline derivatives via two novel synthetic routes using commercially available starting materials, with good to excellent yields and evaluated their anticancer activity against the NCI-60 cancer cell lines. The one-dose (10 μM) anticancer screening of the synthesized compounds in the NCI-60 cell line panel revealed that the substituents have a significant role in the activity. In particular, the indole (7f), imidazole (7g),?and benzimidazole (7h) derivatives showed significant activity against the triple-negative breast cancer cell line, MDA-MB-468. The lead compounds also exhibited notable IC50 values against another breast cancer cell line, MCF-7. Furthermore, it was observed that these compounds were relatively nontoxic to normal cell lines: HEK293 (human embryonic kidney cell line) and MCF12A (nontumorigenic human breast epithelial cell line). The IC50 values against healthy cells were at least 5- to 11-fold higher, offering a new class of heterocycles that can be further developed as promising therapeutics for cancer treatment.

Synthesis of indolo- And pyrrolo[1,2-: a] quinoxalinones through a palladium-catalyzed oxidative carbonylation of the C 2 position of indole

A methodology that involves the Pd-catalyzed direct C(sp2)-H bond carbonylation of the C2 position of indole has been introduced for the synthesis of indolo[1,2-a]quinoxalin-6(5H)-ones. The methodology developed herein was used for the synthesis of pyrrolo[1,2-a]quinoxalin-4(5H)-ones. The reaction of N-substituted 2-(1H-indol-1-yl)anilines or 2-(1H-pyrrol-1-yl)anilines and carbon monoxide in the presence of Pd(OCOCF3)2 as a catalyst and Cu(OAc)2 as an oxidant in toluene at 80 °C forms the corresponding quinoxalinones as exclusive products in good yields. The catalytically active C-H activated intermediate Pd complex was isolated and characterized for the first time which on exposure to CO gas in toluene at 80 °C gave the corresponding quinoxalinone derivative. On the basis of isolation of the intermediate, a possible mechanism has been proposed for the C-H activated direct carbonylative annulation of 2-(5-methoxy-1H-indol-1-yl)-N,4-dimethylaniline.

Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8

The latency-associated nuclear antigen (LANA) is required for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. It acts via replicating and tethering the virus episome to the host chromatin and exerts other functions. We conceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA and the viral genome. We applied a biophysical screening cascade and identified the first LANA binders from small, structurally diverse compound libraries. Starting from a fragment-sized scaffold, we generated optimized hits via fragment growing using a dedicated fluorescence-polarization-based assay as the structure-activity-relationship driver. We improved compound potency to the double-digit micromolar range. Importantly, we qualified the resulting hit through orthogonal methods employing EMSA, STD-NMR, and MST methodologies. This optimized hit provides an ideal starting point for subsequent hit-to-lead campaigns providing evident target-binding, suitable ligand efficiencies, and favorable physicochemical properties.

Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8

The latency-associated nuclear antigen (LANA) is required for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. It acts via replicating and tethering the virus episome to the host chromatin and exerts other functions. We conceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA and the viral genome. We applied a biophysical screening cascade and identified the first LANA binders from small, structurally diverse compound libraries. Starting from a fragment-sized scaffold, we generated optimized hits via fragment growing using a dedicated fluorescence-polarization-based assay as the structure-activity-relationship driver. We improved compound potency to the double-digit micromolar range. Importantly, we qualified the resulting hit through orthogonal methods employing EMSA, STD-NMR, and MST methodologies. This optimized hit provides an ideal starting point for subsequent hit-to-lead campaigns providing evident target-binding, suitable ligand efficiencies, and favorable physicochemical properties.

ORGANOMETALLIC COMPLEX AND APPLICATION THEREOF IN ELECTRONIC DEVICES

Disclosed are an organometallic complex comprising a new six-membered N-heterocyclic ligand, and an application thereof in an organic electronic device, especially in a phosphorescent organic light-emitting diode. The present invention further relates to

A catalytic intramolecular nitrene insertion into a copper(i)-N-heterocyclic carbene bond yielding fused nitrogen heterocycles

N-(2-Azidophenyl)azolium salts were easily prepared and reacted with copper(i) under conditions allowing the formation of NHC complexes. Under these conditions, the formation of benzimidazo-fused heterocycles occurred under catalytic, efficient and very mild conditions. This reaction is proposed to proceed via dinitrogen elimination and imido/nitrene-NHC cyclization.

NEW NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND ORGANIC ELECTRONIC DEVICE USING THE SAME

The present invention refers to novel nitrogenous heterocyclic and optical material using it organic electronic device with high. The present invention according to organic electronic devices efficiency, excellent characteristics such as voltage and life blades, presenting a. (by machine translation)

Sequential decarboxylative azide-alkyne cycloaddition and dehydrogenative coupling reactions: One-pot synthesis of polycyclic fused triazoles

Herein, we describe a one-pot protocol for the synthesis of a novel series of polycyclic triazole derivatives. Transition metalcatalyzed decarboxylative CuAAC and dehydrogenative cross coupling reactions are combined in a single flask and achieved good yi

Copper-catalyzed aerobic oxidative intramolecular C-H amination leading to imidazobenzimidazole derivatives

A highly efficient copper-catalyzed aerobic oxidative intramolecular C-H amination has been developed using substituted 2-(1H-imidazol-1-yl)-N- alkylbenzenamines as the starting materials, and the corresponding imidazobenzimidazole derivatives were obtain

Copper-catalyzed N-arylation of imidazoles and benzimidazoles

(Chemical Equation Presented) 4,7-Dimethoxy-1,10-phenanthroline (L1c) was found to be an efficient ligand for the copper-catalyzed N-arylation of imidazoles and benzimidazoles with both aryl iodides and bromides under mild conditions. Further optimization of the system has revealed that the addition of poly(ethylene glycol) accelerates this reaction. A variety of hindered and functionalized imidazoles, benzimidazoles, and aryl halides were transformed in good to excellent yields. Heteroaryl halides were also coupled in moderate to good yields. We also present the results obtained from a series of coupling reactions, which directly compare the use of L1c with other recently reported ligands.